Anteris Reports 2025 Financial Results and Provides Corporate Update
AVR has more than doubled off its 52-week low of $2.34.
Summary
Anteris Technologies reported its 2025 financial results, including $77.8 million in net operating cash outflows, alongside a highly significant corporate update. The company completed $320 million in capital raises in early 2026, notably including a strategic investment from Medtronic, which is a transformative event given its size relative to the company's market cap. This substantial funding is critical for advancing the global pivotal PARADIGM Trial for its DurAVR® THV, which received FDA Investigational Device Exemption (IDE) approval in Q4 2025 and has already enrolled its first patients. The company also reported favorable 30-day and 1-year clinical outcomes and appointed two new independent directors. This news provides crucial financial stability and strong clinical momentum, positioning Anteris for its path to commercialization. Investors should monitor the ongoing progress of the PARADIGM Trial and further developments from the Medtronic partnership.
At the time of this announcement, AVR was trading at $6.22 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $261.2M. The 52-week trading range was $2.34 to $8.36. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.